By IDSE News Staff
The Department of Health and Human Services (HHS) updated its guidelines on treating children with HIV.
One of the biggest updates was the inclusion of long-acting, injectable cabotegravir and rilpivirine (Cabenuva, ViiV Healthcare/Janssen), after the FDA changed the indication to include children and adolescents 12 years of age and older and weighing at least 35 kg.